Cancer cases in the US continued to be underdiagnosed during the second year of the COVID-19 pandemic

Researchers examine how the COVID-19 pandemic affected cancer diagnosis rates between 2021 and 2020.

ChromaDex wins orphan designation for rare ataxia drug – Pharmaceutical Technology

Ataxia telangiectasia is a rare, inherited, progressive childhood disorder for which symptoms manifest neurologically and immunologically. Chromadex is developing a candidate to treat ataxia telangiectasia.

June 7, 2024

Ketamine’s rapid impact on depression linked to immune system pathways

Study reveals ketamine’s potent anti-inflammatory effects on neurological disorders, showing promise for treating major depressive disorder through modulation of neuroimmune pathways.

April 15, 2024

Disc teases potential NDA for rare skin disorder drug – Pharmaceutical Technology

EPP causes severe burn injuries on the skin after as little as ten minutes of exposure to visible light. Credit: Korawat photo shoot via Shutterstock.

November 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.